{
    "thread": {
        "uuid": "8ba7288d0ae06a9c89eef3563a2d2fab4aceffd8",
        "url": "https://markets.businessinsider.com/news/stocks/abivax-sa-strong-progress-in-phase-3-trials-and-solid-financial-position-justify-buy-rating-1034211735",
        "site_full": "markets.businessinsider.com",
        "site": "businessinsider.com",
        "site_section": "https://markets.businessinsider.com/news",
        "site_categories": [
            "investing",
            "financial_news",
            "finance",
            "top_news_nz",
            "top_news_au",
            "top_news_ae",
            "top_news_us",
            "top_news_gb",
            "top_news_th",
            "top_news_sg",
            "top_news_rs",
            "top_news_ph",
            "top_news_hk",
            "top_news_qa",
            "top_news_ie",
            "top_news_pk",
            "top_news_se",
            "top_news_id",
            "top_news_dk",
            "top_news_za",
            "top_news_my",
            "top_news_il",
            "top_news_kw",
            "top_news_fi",
            "top_news_ca",
            "top_news"
        ],
        "section_title": "News | Financial and Business News | Markets Insider",
        "title": "Abivax SA: Strong Progress in Phase 3 Trials and Solid Financial Position Justify Buy Rating",
        "title_full": "Abivax SA: Strong Progress in Phase 3 Trials and Solid Financial Position Justify Buy Rating",
        "published": "2025-01-09T22:25:00.000+02:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "US",
        "main_image": "",
        "performance_score": 0,
        "domain_rank": 125,
        "domain_rank_updated": "2025-01-06T23:00:00.000+02:00",
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "8ba7288d0ae06a9c89eef3563a2d2fab4aceffd8",
    "url": "https://markets.businessinsider.com/news/stocks/abivax-sa-strong-progress-in-phase-3-trials-and-solid-financial-position-justify-buy-rating-1034211735",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Tipranks",
    "published": "2025-01-09T22:25:00.000+02:00",
    "title": "Abivax SA: Strong Progress in Phase 3 Trials and Solid Financial Position Justify Buy Rating",
    "text": "Abivax SA: Strong Progress in Phase 3 Trials and Solid Financial Position Justify Buy Rating\nJMP Securities analyst [Jason Butler](https://www.tipranks.com/experts/analysts/jason-butler?utm_source=markets.businessinsider.com&utm_medium=referral) reiterated a Buy rating on Abivax SA Sponsored ADR ([ABVX](https://www.tipranks.com/stocks/abvx?utm_source=markets.businessinsider.com&utm_medium=referral) – [Research Report](https://www.tipranks.com/subscribe/research-report/?symbol=abvx&ref=MCO_STOCK&refersTo=&merge=Markets&utm_source=markets.businessinsider.com&utm_medium=referral)) today and set a price target of $33.00.\nStay Ahead of the Market:\n- Discover outperforming stocks and invest smarter with\n[Top Smart Score Stocks](https://www.tipranks.com/screener/top-smart-score-stocks?utm_source=markets.businessinsider.com&utm_medium=referral) - Filter, analyze, and streamline your search for investment opportunities using\n[Tipranks' Stock Screener](https://www.tipranks.com/screener/stocks?utm_source=markets.businessinsider.com&utm_medium=referral)\nJason Butler has given his Buy rating due to a combination of factors indicating strong progress and potential for Abivax SA Sponsored ADR. The company is advancing well with its Phase 3 trials for obefazimod in treating ulcerative colitis, having surpassed 80% enrollment. This progress suggests a timely completion of the study with results expected in the third quarter of 2025, which strengthens confidence in the stock’s future performance.\nAdditionally, the consistency of the patient characteristics with previous trials and the company’s strategic enrollment efforts further enhance the outlook. Abivax’s solid financial position, with sufficient cash to sustain operations beyond the Phase 3 results, adds to the positive sentiment. As a result, these factors contribute to a high-conviction outlook, justifying the Buy rating from Jason Butler.\nTipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your [TipRanks Premium](https://www.tipranks.com/go-premium-checkout?utm_source=markets.businessinsider.com&utm_medium=referral) journey today.\nAbivax SA Sponsored ADR (ABVX) Company Description:\nAbivax is focused on developing innovative treatments that harness the body¿s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
        "Economy, Business and Finance"
    ],
    "topics": [
        "Economy, Business and Finance->financial and economic news",
        "Economy, Business and Finance->business reporting and performance"
    ],
    "ai_allow": true,
    "has_canonical": true,
    "breaking": null,
    "webz_reporter": false,
    "external_links": [
        "https://www.tipranks.com/screener/stocks?utm_source=markets.businessinsider.com&utm_medium=referral",
        "https://www.tipranks.com/screener/top-smart-score-stocks?utm_source=markets.businessinsider.com&utm_medium=referral",
        "https://www.tipranks.com/subscribe/research-report/?symbol=abvx&ref=MCO_STOCK&refersTo=&merge=Markets&utm_source=markets.businessinsider.com&utm_medium=referral",
        "https://www.tipranks.com/stocks/abvx?utm_source=markets.businessinsider.com&utm_medium=referral",
        "https://www.tipranks.com/go-premium-checkout?utm_source=markets.businessinsider.com&utm_medium=referral",
        "https://www.tipranks.com/experts/analysts/jason-butler?utm_source=markets.businessinsider.com&utm_medium=referral",
        "https://www.tipranks.com/screener/top-smart-score-stocks",
        "https://www.tipranks.com/stocks/abvx",
        "https://tipranks.com/experts/analysts/jason-butler?utm_source=markets.businessinsider.com&utm_medium=referral",
        "https://www.tipranks.com/go-premium-checkout",
        "https://www.tipranks.com/screener/stocks",
        "https://tipranks.com/subscribe/research-report/?symbol=abvx&ref=MCO_STOCK&refersTo=&merge=Markets&utm_source=markets.businessinsider.com&utm_medium=referral",
        "https://tipranks.com/stocks/abvx?utm_source=markets.businessinsider.com&utm_medium=referral",
        "https://tipranks.com/screener/stocks?utm_source=markets.businessinsider.com&utm_medium=referral",
        "https://tipranks.com/go-premium-checkout?utm_source=markets.businessinsider.com&utm_medium=referral",
        "https://tipranks.com/screener/top-smart-score-stocks?utm_source=markets.businessinsider.com&utm_medium=referral",
        "https://www.tipranks.com/experts/analysts/jason-butler",
        "https://www.tipranks.com/subscribe/research-report/"
    ],
    "external_images": [],
    "entities": {
        "persons": [
            {
                "name": "Jason Butler",
                "sentiment": "none"
            }
        ],
        "organizations": [],
        "locations": []
    },
    "syndication": {
        "syndicated": false,
        "syndicate_id": "8ba7288d0ae06a9c89eef3563a2d2fab4aceffd8",
        "first_syndicated": true
    },
    "rating": null,
    "crawled": "2025-01-10T02:34:44.685+02:00",
    "updated": "2025-01-10T02:34:44.685+02:00"
}